NCT04897750View on ClinicalTrials.gov

Pharmacokinetic Study of Intranasal CT001 in Children 1-17 Years of Age Undergoing Elective Surgical Procedures

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 19, 2021

Primary Completion Date

May 16, 2022

Study Completion Date

May 16, 2022

Conditions
Analgesia
Interventions
COMBINATION_PRODUCT

CT001

Sufentanil 0.5 mcg/kg + ketamine 0.5 mg/kg as nasal spray, followed by an additional dose 10 -15 minutes after, if needed.

Trial Locations (1)

2100

Anæstesi- og Operationsafdelingen 4013 Juliane Marie Centeret, Copenhagen

Sponsors

Lead Sponsor

Cessatech A/S
All Listed Sponsors
lead

Cessatech A/S

INDUSTRY

NCT04897750 - Pharmacokinetic Study of Intranasal CT001 in Children 1-17 Years of Age Undergoing Elective Surgical Procedures | Biotech Hunter | Biotech Hunter